Cancer NetworkOriginal article
<![CDATA[Ris-Rez Hits PFS End Point in Phase 3 Osteosarcoma Trial]]>
Phase 3positiverisvutatug rezetecanPositive
AI Analysis
Summary
Risvutatug rezetecan met its primary endpoint of improved progression-free survival in the Phase 3 ARTEMIS-011 trial for patients with relapsed osteosarcoma.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
improved progression-free survival
Importance:7/10
Sentiment:
0.80
Phase 3osteosarcomaoncologyprogression-free survival
Read the original article
Published by Cancer Network on July 28, 2026 4:00 PM